The recent deaths of celebrities like Michael Jackson, Anna Nicole Smith, Heath Ledger, and Whitney Houston have shown a spotlight on the overuse and abuse of prescription drugs. Most people believe that prescription drugs are safer than illegal substances. But, when combined with other over-the-counter sedatives, prescription drugs can be every bit as powerful, addictive, and dangerous. In 2006, overdoses on a class of prescription pain relievers called opioid analgesics killed more people than those killed by overdoses on cocaine and heroin combined. Right now, among 35 to 54 year olds, poisoning by prescription drugs is the most common cause of accidental death—even more so than auto-related deaths. In Medicines That Kill, Dr. Marcum shines a light on the addictive power of prescription medication and how you can protect yourself and your family by practicing healthy habits.
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
PRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the pharmaceutical industries and their charade of fraudulent behaviour, both in research and marketing where the morally repugnant disregard for human lives is the norm. He convincingly draws close co
A veteran board-certified pharmacist cites the high number of annual deaths associated with prescription drug side effects, calling for changes in prescription practices that account for the needs of aging bodies.
A classic since its first publication nearly 25 years ago, Stoelting's Anesthesia and Co-Existing Disease, 7th Edition, by Drs. Roberta L. Hines and Katherine E. Marschall, remains your go-to reference for concise, thorough coverage of pathophysiology of the most common diseases and their medical management relevant to anesthesia. To provide the guidance you need to successfully manage or avoid complications stemming from pre-existing conditions there are detailed discussions of each disease, the latest practice guidelines, easy-to-follow treatment algorithms, and more. Presents detailed discussions of common diseases, as well as highlights of more rare diseases and their unique features that could be of importance in the perioperative period. Examines specific anesthesia considerations for special patient populations—including pediatric, obstetric and elderly patients. Features abundant figures, tables, diagrams, and photos to provide fast access to the most pertinent aspects of every condition and to clarify critical points about management of these medical illnesses. Ideal for anesthesiologists in practice and for anesthesia residents in training and preparing for boards. Includes brand new chapters on sleep-disordered breathing, critical care medicine and diseases of aging as well as major updates of nearly all other chapters. Covers respiratory disease in greater detail with newly separated chapters on Sleep Disordered Breathing; Obstructive Lung Disease; Restrictive Lung Disease; and Respiratory Failure. Provides the latest practice guidelines, now integrated into each chapter for quick reference.
The use of drugs in food animal production has resulted in benefits throughout the food industry; however, their use has also raised public health safety concerns. The Use of Drugs in Food Animals provides an overview of why and how drugs are used in the major food-producing animal industriesâ€"poultry, dairy, beef, swine, and aquaculture. The volume discusses the prevalence of human pathogens in foods of animal origin. It also addresses the transfer of resistance in animal microbes to human pathogens and the resulting risk of human disease. The committee offers analysis and insight into these areas: Monitoring of drug residues. The book provides a brief overview of how the FDA and USDA monitor drug residues in foods of animal origin and describes quality assurance programs initiated by the poultry, dairy, beef, and swine industries. Antibiotic resistance. The committee reports what is known about this controversial problem and its potential effect on human health. The volume also looks at how drug use may be minimized with new approaches in genetics, nutrition, and animal management.
In this book, "All Medicines are Poison!," Melvin H. Kirschner, MPH, MD, sets out to remove the fog of confusion that clouds the landscape patients are required to navigate in their search for health care today. This book describes the risks and benefits associated with the use of medicines, and explores the validity of other treatment modalities referred to as "Complimentary and Alternative Medicine (CAM). He discusses the numerous failings and backroom dealings in the pharmaceutical and insurance industries, and highlights possible solutions to many of these current concerns. Dr. Kirschner has had an extensive career in the healthcare field. He has championed patient's rights throughout his career. As one of the key physicians instrumental in the enactment of the first biomedical ethical guidelines in the world, he has always strived for close doctor/patient relationships where the patient's concerns always come first.
This hard-hitting expose does for prescription drugs what "Silent Spring" did for pesticides, revealing the hidden dangers of the most commonly prescribed medications--and what the consumer can do to minimize the risks of serious side effects.
The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.
Experts estimate that as many as 98,000 people die in any given year from medical errors that occur in hospitals. That's more than die from motor vehicle accidents, breast cancer, or AIDSâ€"three causes that receive far more public attention. Indeed, more people die annually from medication errors than from workplace injuries. Add the financial cost to the human tragedy, and medical error easily rises to the top ranks of urgent, widespread public problems. To Err Is Human breaks the silence that has surrounded medical errors and their consequenceâ€"but not by pointing fingers at caring health care professionals who make honest mistakes. After all, to err is human. Instead, this book sets forth a national agendaâ€"with state and local implicationsâ€"for reducing medical errors and improving patient safety through the design of a safer health system. This volume reveals the often startling statistics of medical error and the disparity between the incidence of error and public perception of it, given many patients' expectations that the medical profession always performs perfectly. A careful examination is made of how the surrounding forces of legislation, regulation, and market activity influence the quality of care provided by health care organizations and then looks at their handling of medical mistakes. Using a detailed case study, the book reviews the current understanding of why these mistakes happen. A key theme is that legitimate liability concerns discourage reporting of errorsâ€"which begs the question, "How can we learn from our mistakes?" Balancing regulatory versus market-based initiatives and public versus private efforts, the Institute of Medicine presents wide-ranging recommendations for improving patient safety, in the areas of leadership, improved data collection and analysis, and development of effective systems at the level of direct patient care. To Err Is Human asserts that the problem is not bad people in health careâ€"it is that good people are working in bad systems that need to be made safer. Comprehensive and straightforward, this book offers a clear prescription for raising the level of patient safety in American health care. It also explains how patients themselves can influence the quality of care that they receive once they check into the hospital. This book will be vitally important to federal, state, and local health policy makers and regulators, health professional licensing officials, hospital administrators, medical educators and students, health caregivers, health journalists, patient advocatesâ€"as well as patients themselves. First in a series of publications from the Quality of Health Care in America, a project initiated by the Institute of Medicine
